Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03290950 · ClinicalTrials.gov registry record · Phase 2

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
75
Enrollment target
7
Study locations

NCT03290950: Active Phase 2 study of Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.

NCT03290950 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 75 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (86% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03290950, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
75 participants
Enrollment target
7
Study locations

Study Summary

This is a study to test the safety and effectiveness of the study drug, daratumumab in combination with carfilzomib, lenalidomide and dexamethasone. The purpose of this study is to test whether giving daratumumab along with the other drugs (carfilzomib, lenalidomide and dexamethasone) is safe for patients.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG dexamethasone
  • DRUG lenalidomide
  • DRUG carfilzomib
  • DRUG daratumumab

Study Locations (7)

New York

  • Memorial Sloan Kettering Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2017-09-25
Est. Completion 2026-09
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03290950

The ClinicalTrials.gov registry entry for NCT03290950 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (86% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which dexamethasone is the first listed.

NCT03290950 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT03290950 about?

NCT03290950 is a clinical study titled "A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma". This is a study to test the safety and effectiveness of the study drug, daratumumab in combination with carfilzomib, lenalidomide and dexamethasone. The purpose of this study is to test whether giving daratumumab along with the other drugs (carfilzomib, lenalidomide and dexamethasone) is safe for pa...

What is the current status of trial NCT03290950?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2017-09-25. Estimated completion is 2026-09.

What conditions does trial NCT03290950 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT03290950?

The interventions under investigation include: dexamethasone (DRUG), lenalidomide (DRUG), carfilzomib (DRUG), daratumumab (DRUG).

Who is sponsoring clinical trial NCT03290950?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03290950 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.